Related Experiment Videos
Systemic treatment of metastatic breast cancer
1Royal Marsden Hospital, Institute of Cancer Research, London SW3 6JJ.
Hospital Medicine (London, England : 1998)
|June 2, 2001
Abstract:
This article reviews recent advances in the treatment of metastatic breast cancer, in particular the results of randomized controlled phase III clinical trials. These have led to the evidence-based introduction of several new drugs including aromatase inhibitors, taxanes and bisphosphonates, some of which have been shown to impact on overall survival.
Insights
Recent advances in metastatic breast cancer treatment include new drugs like aromatase inhibitors and taxanes. Evidence from phase III trials shows these therapies improve overall survival for patients with advanced disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic breast cancer (MBC) presents significant treatment challenges.
- Advances in therapeutic strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To review recent evidence-based advancements in MBC treatment.
- To highlight the impact of new drugs from phase III clinical trials.
Main Methods:
- Review of randomized controlled phase III clinical trials in MBC.
- Analysis of data on novel therapeutic agents.
Main Results:
- Introduction of aromatase inhibitors, taxanes, and bisphosphonates into clinical practice.
- Demonstrated impact of these agents on overall survival in MBC patients.
Conclusions:
- New drug classes have significantly advanced MBC treatment.
- Phase III trial evidence supports the efficacy of these novel therapies in improving survival.